Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
bioAffinity TechnologiesBIAF -8.69%44 3-1 Month Momentum % is -61.93% as of Aug. 04, 2026. GuruFocus rates BIAF with a GF Score™ of 44/100 and a GF Value™ of $4.00 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, bioAffinity Technologies ranks worse than 98.6% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-04), bioAffinity Technologies's 3-1 Month Momentum % is -61.93%.
The industry rank for bioAffinity Technologies's 3-1 Month Momentum % or its related term are showing as below:
BIAF's 3-1 Month Momentum % is ranked worse than 98.6% of 215
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.27
vs BIAF: -61.93
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
bioAffinity Technologies 3-1 Month Momentum % Related Terms
BIAF vs FUNI, ISPC, NDRA: 3-1 Month Momentum % Comparison
For the Diagnostics & Research subindustry, bioAffinity Technologies's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
bioAffinity Technologies 3-1 Month Momentum % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, bioAffinity Technologies's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where bioAffinity Technologies's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
bioAffinity Technologies (BIAF) has a 3-1 Month Momentum % of -61.93% as of Aug. 04, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on bioAffinity Technologies and its competitors. According to the industry distribution chart, bioAffinity Technologies ranks #212 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 98.6%.
Is bioAffinity Technologies' 3-1 Month Momentum % too high?
bioAffinity Technologies' current 3-1 Month Momentum % is -61.93%. Based on the distribution chart, bioAffinity Technologies ranks #212 out of 215 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, bioAffinity Technologies has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does bioAffinity Technologies' 3-1 Month Momentum % compare to FUNI and ISPC?
According to the Medical Diagnostics & Research industry distribution chart, bioAffinity Technologies ranks #212 out of 215 companies for 3-1 Month Momentum %. This places bioAffinity Technologies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Diagnostics & Research company?
A good 3-1 Month Momentum % depends on the Medical Diagnostics & Research industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on bioAffinity Technologies and its competitors. bioAffinity Technologies's current 3-1 Month Momentum % is -61.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is bioAffinity Technologies stock overvalued right now?
Based on GuruFocus' analysis, bioAffinity Technologies (BIAF) is currently considered Possible Value Trap. The stock's GF Value™ is $4.00, compared to a current price of $0.56 — trading 86.1% below its estimated fair value. The current 3-1 Month Momentum % is -61.93%. bioAffinity Technologies' overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For bioAffinity Technologies (BIAF), the current 3-1 Month Momentum % is -61.93% as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is bioAffinity Technologies (BIAF) Overvalued in 2026?
Based on GuruFocus' analysis, bioAffinity Technologies stock appears to be undervalued.
The current stock price of $0.56 is trading 86.1% below its estimated GF Value™ of $4.00.
GuruFocus considers bioAffinity Technologies to be Possible Value Trap.
Key valuation signals for BIAF:
3-1 Month Momentum %: -61.93%
GF Value™: $4.00 vs. price of $0.56 (86.1% below fair value)
No single metric tells the full story. See the BIAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
44GF Score
Get the complete analysis for BIAF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIAF has been successfully added to your 
